Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px
Document › Details

Rentschler Biotechnologie GmbH. (2/15/16). "Press Release: Rentschler Appoints Stefan Rampf to the Position of CFO". Laupheim.

Organisation Organisation Rentschler Biotechnologie GmbH
  Today Rentschler Biopharma SE
  Group Rentschler (Group)
Products Product contract manufacturing (biologicals)
  Product 2 recombinant protein production in mammalian cells
Persons Person Rampf, Stefan (Rentschler 201605– CFO before ABL Technik Entlackung GmbH + Volvo Financial Services in Ffm)
  Person 2 Mathias, Frank (Rentschler 201604– CEO before Medigene + Amgen GmbH + Servier DE + Hoechst)

Rentschler Biotechnologie, a leading contract organization for the development and manufacturing of biopharmaceuticals announces the appointment of Stefan Rampf as new Chief Financial Officer (CFO) effective May 1st, 2016.

Stefan Rampf will be responsible for Commercial Management. The 49-year-old has about one decade’s experience as CFO with renowned companies, most recently with ABL Technik Entlackung GmbH, Leutkirch, and, until 2013, with Volvo Financial Services in Frankfurt.

Dr. Nikolaus F. Rentschler: “Stefan Rampf convinces through his excellent expertise and strengthens the Top Management of Rentschler Biotechnologie on its successful way. The Supervisory Board and Management Board are very much looking forward to the cooperation.”

Dr. Frank Mathias: “With Stefan Rampf joining Rentschler, the new Management Board will be complete. Together with Thomas Siklosi and the whole Management Team we will continue our close and successful cooperation with our partners and clients and jointly bring the company forward.”

About Rentschler Biotechnologie

Rentschler is a full-service Contract Development and Manufacturing Organization (CDMO) and one of the leaders in the industry. With many years of experience the company is a reliable outsourcing partner. Focused on mammalian cell lines, the experience covers the development and manufacturing of biopharmaceuticals for clients, supporting them through to market approval of their products. The high quality of the consulting services and the competent implementation of cGMP and quality management standards ensure the project success. Cutting-edge technologies and cGMP facilities with stainless steel and single-use bioreactors support the flexible and customized cost-efficient manufacturing for clinical studies and market supply. Rentschler is a privately owned company which can act independently on a long-term basis.


Dr. Marion Schrader
Senior Director Marketing
+49 7392 701-491

Record changed: 2016-02-16


Picture [LSA] – The Business Web Portal 650x89px

More documents for Rentschler (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture EBD Group BIO-Europe 2019 Hamburg Germany BEU2019 650x80px

» top